What is Dactinomycin?

DACTINOMYCIN is for the treatment of adult and pediatric patients with Wilms tumor, with rhabdomyosarcoma, with Ewing sarcoma, with metastatic, nonseminomatous testicular cancer, post-menarchal patients with gestational trophoblastic neoplasia, adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion.

Uses of Dactinomycin

  • Adult patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen.
  • Adult and pediatric patients with rhabdomyosarcoma, as part of a multiphase, combination chemotherapy regimen.
  • Adult and also pediatric patients with Ewing sarcoma, as a multi-phase, combination chemotherapy regimen.
  • Patients (Adult and pediatric) with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination regimen chemotherapy regimen.
  • Postmenarchal patients who are carrying gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen.
  • Such adult patients who are locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion.
  • The combination of Dactinomycin and Doxorubicin can be used against advanced sarcomas.

Dosage:

  • The dactinomycin 0.5 mg injection should always be given intravenously over the 10-15 minutes. Do not use in-line filters with the cellulose ester membrane.
  • The recommended dose of actinomycin D for the Wilms Tumor is 45 mcg/kg should be given intravenously once every 3-6 weeks for up to 26 weeks.
  • The recommended dose of dactinomycin for Rhabdomyosarcoma is 15 mcg/kg should be given intravenously once daily for 5 days every 3-9 weeks for up to 112 weeks.
  • The recommended dose of actinomycin for Ewing Sarcoma is 1250 mcg/m should be given intravenously once every 3 weeks for 51 weeks.
  • The recommended dose of dactinomycin for Metastatic Nons eminomatous Testicular Cancer is 1000 mcg/m should be given intravenously once every 3 weeks for 12 weeks.
  • The recommended dose of actinomycin d for Gestational Trophoblastic Neoplasia is 500 mcg intravenously on Days 1 and 2 every 2 weeks for up to 8 weeks.
  • The recommended dose of dactinomycin together with the melphalan for Regional Perfusion in the Locally Recurrent and Locoregional Solid Malignancies is 50 mcg/kg once for lower pelvis and 35 mcg/kg once for upper pelvis.